23 August 2016 - The MHRA has published its EAMS scientific opinion on venetoclax for the treatment of adults with chronic lymphocytic leukaemia.

The early access to medicines scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.

Under the scheme, the MHRA will give a scientific opinion on the benefit/risk balance of the medicine, based on the data available when the EAMS submission was made.

Read MHRA EAMS public assessment report for venetoclax